• Türkçe
    • English
  • Türkçe 
    • Türkçe
    • English
  • Giriş
Öğe Göster 
  •   Açık Erişim Ana Sayfası
  • Avesis
  • Dokümanı Olmayanlar
  • Makale
  • Öğe Göster
  •   Açık Erişim Ana Sayfası
  • Avesis
  • Dokümanı Olmayanlar
  • Makale
  • Öğe Göster
JavaScript is disabled for your browser. Some features of this site may not work without it.

Lower erythropoietin and iron supplementation are required in hemodialysis patients with hepatitis C virus infection

Tarih
2004
Yazar
Tonbul, Z
Turk, S
Kurtoglu, E
Yeksan, M
Yildiz, A
Altintepe, L
Üst veri
Tüm öğe kaydını göster
Özet
Background: Chronic hepatitis C virus (HCV) infection is a common infectious agent in chronic hemodialysis (HD) patients. In this prospective case-control study, we aimed to investigate the influence of chronic HCV infection on erythropoietin (EPO) and iron requirement in HD patients. Patients and methods: 49 HD patients (24 male, 25 female, mean age 47 +/- 15 years) were included. The mean time spent on dialysis was 39 +/- 38 months, and follow-up time was 1 year for this study. Biochemical analyses and complete blood counts together with iron status of the patients (transferrin saturation and serum ferritin levels) were measured monthly. Highly sensitive C-reactive protein (hs-CRP) levels were measured within 3-month intervals. Endogenous EPO levels were measured by enzyme-linked immunoassay 2 weeks after cessation of EPO treatment. Results: Eleven of the HD patients (22%) were anti-HCV(+). There was no difference in age, sex, time on dialysis, distribution of primary renal diseases, predialytic BUN, Kt/V, albumin and i-PTH levels between HCV(+) and (-) patients. Anti-HCV-positive patients required significantly lower weekly doses of EPO (87 +/- 25 IU/kg vs 129 +/- 11 IU/kg, p = 0.042) and iron (16.8 +/- 12.2 mg vs 32.6 +/- 16.1 mg, p = 0.02) replacement than anti-HCV(-) group; hs-CRP levels were similar between study groups. Serum endogenous EPO levels were significantly higher in HCV(+) patients than HCV(-) HD patients (9.43 +/- 6.47 mU/ml vs 3.59 +/- 2.08 mU/ml, p = 0.008). Conclusion: Anti-HCV(+) HD patients had higher serum EPO levels and required less EPO and iron replacement as compared to anti-HCV(-) patients. Because of the changes in iron metabolism, iron treatment should be carefully administered in HD patients with HCV.
Bağlantı
http://hdl.handle.net/20.500.12627/95531
https://doi.org/10.5414/cnp61347
Koleksiyonlar
  • Makale [92796]

Creative Commons Lisansı

İstanbul Üniversitesi Akademik Arşiv Sistemi (ilgili içerikte aksi belirtilmediği sürece) Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.

DSpace software copyright © 2002-2016  DuraSpace
İletişim | Geri Bildirim
Theme by 
Atmire NV
 

 


Hakkımızda
Açık Erişim PolitikasıVeri Giriş Rehberleriİletişim
sherpa/romeo
Dergi Adı/ISSN || Yayıncı

Exact phrase only All keywords Any

BaşlıkbaşlayaniçerenISSN

Göz at

Tüm DSpaceBölümler & KoleksiyonlarTarihe GöreYazara GöreBaşlığa GöreKonuya GöreTürlere GöreBu KoleksiyonTarihe GöreYazara GöreBaşlığa GöreKonuya GöreTürlere Göre

Hesabım

GirişKayıt

Creative Commons Lisansı

İstanbul Üniversitesi Akademik Arşiv Sistemi (ilgili içerikte aksi belirtilmediği sürece) Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.

DSpace software copyright © 2002-2016  DuraSpace
İletişim | Geri Bildirim
Theme by 
Atmire NV